Evidence map›Paper›PMID 36105930›Full record

ReviewBioMed research international2022

Multidrug-Resistant Bacteria: Their Mechanism of Action and Prophylaxis.

Alok Bharadwaj, Amisha Rastogi, Swadha Pandey, Saurabh Gupta, Jagdip Singh Sohal

Registry-linked trialAbstract readReview
In one paragraph

Review in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07167173 (Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis), which is not on this map. Cited by 80 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07167173 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis

TypeobservationalSponsorHospital Italiano de Buenos AiresRan2025 to 2025Enrolled10,000ConditionsSepsis, Septic Shock
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. BiogenicRSC advances · 2026
    Article
  7. Article
  8. Article
  9. Antibiotics (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alok BharadwajDepartment of Biotechnology, GLA University, Mathura (U.P.)-281 406, India.ORCID https://orcid.org/0000-0002-7383-188X
Amisha RastogiDepartment of Biotechnology, GLA University, Mathura (U.P.)-281 406, India.ORCID https://orcid.org/0000-0003-1153-4529
Swadha PandeyDepartment of Biotechnology, GLA University, Mathura (U.P.)-281 406, India.ORCID https://orcid.org/0000-0002-3866-0640
Saurabh GuptaDepartment of Biotechnology, GLA University, Mathura (U.P.)-281 406, India.ORCID https://orcid.org/0000-0001-8140-2033
Jagdip Singh SohalDepartment of Biotechnology, GLA University, Mathura (U.P.)-281 406, India.ORCID https://orcid.org/0000-0003-4797-9466

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present scenario, resistance to antibiotics is one of the crucial issues related to public health. Earlier, such resistance to antibiotics was limited to nosocomial infections, but it has now become a common phenomenon. Several factors, like extensive development, overexploitation of antibiotics, excessive application of broad-spectrum drugs, and a shortage of target-oriented antimicrobial drugs, could be attributed to this condition. Nowadays, there is a rise in the occurrence of these drug-resistant pathogens due to the availability of a small number of effective antimicrobial agents. It has been estimated that if new novel drugs are not discovered or formulated, there would be no effective antibiotic available to treat these deadly resistant pathogens by 2050. For this reason, we have to look for the formulation of some new novel drugs or other options or substitutes to treat such multidrug-resistant microorganisms (MDR). The current review focuses on the evolution of the most common multidrug-resistant bacteria and discusses how these bacteria escape the effects of targeted antibiotics and become multidrug resistant. In addition, we also discuss some alternative mechanisms to prevent their infection as well.

Indexed as

Cross InfectionDrug Resistance, Multiple, BacterialAnti-Bacterial AgentsBacteriaHumansAnti-Bacterial Agents

Identifiers

PMID36105930
PMCPMC9467707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.